IL6R and systemic inflammatory response syndrome: In the LPS‐induced murine SIRS model, we found that both the commercial IL‐6R mAb Tocilizumab and the prepared h‐mIL‐6R mAb alleviated systemic inflammatory responses, organ dysfunctions, and improved survival rates.